Advanced Medical Isotope changes name
Medical isotope developer Advanced Medical Isotope has changed its name to...Read more on AuntMinnie.comRelated Reading: AMIC reports progress on RadioGel FDA clearance AMIC resubmits Y-90 RadioGel to FDA AMIC nets brachytherapy-related patent AMIC looks for European investors AMIC and GSG form strategic alliance
After brachytherapy, some choroidal melanomas regress faster than others. Several studies suggest that these tumors are more likely to metastasize than those that regress slowly. Not all authors support this view, some reporting no correlation between tumor regression and monosomy 3, which is highly lethal.1 More research is needed to determine whether tumor regression rate after brachytherapy predicts metastasis.
Conclusions: Feasibility of recruitment into a study of vaginal dilator use was high. Adherence was low, and there was no difference between groups. Adherence to vaginal dilator use requires novel interventions to test. Implications for Practice: Nursing education that includes how dilators may maintain vaginal health may improve use because it was a motivator for adherence in this study.
To recognize the practice of radiotherapy for management of cervical cancer in Ontario, Canada, and to use the results of the survey to harmonize and standardize practice across the province.
In choroidal melanoma the radiation threshold dose for local control remains largely unknown. The present study examined a group of patients that received a wide range of minimum tumor dose in order to investigate a dose-response relationship. A literature review is performed to compare our results with available evidence in brachytherapy and charged particle external beam radiotherapy.
CONCLUSION: When the vicryl coating is used, seeds have a significantly lower propensity to slip from their initial implant locations. This may help maintain dosimetric integrity, warranting further study of postoperative dosimetry. PMID: 29667307 [PubMed - as supplied by publisher]
Publication date: Available online 14 April 2018 Source:Practical Radiation Oncology Author(s): Stephen A. Mihalcik, Jonathan J. Chipman, Martin G. Sanda, Meredith M. Regan, Irving D. Kaplan, Andrew A. Wagner, Catrina M. Crociani, Peter Chang
Publication date: August 2018 Source:Radiation Physics and Chemistry, Volume 149 Author(s): Eshraq Ababneh, Saed Dababneh, Shada Wadi-Ramahi, Jamal Sharaf Unlike for external beam treatment, Model Based Dose Calculation Algorithms for Brachytherapy are still under development, and have been recently encouraged by the American Association of Physicists in Medicine. This delay is at least partially caused by the extreme complications associated with the multidimensional considerations underlying Brachytherapy dose calculations. These algorithms require detailed mathematical description, based on extensive radiation physics ...
This article describes how a targeted application of Lean methodology in a high-volume brachytherapy department can result in significant and sustained change that benefits patients and staff.
(European Association for the Study of the Liver) ILC 2018: The addition of SIRT to sorafenib in patients with advanced hepatocellular carcinoma was associated with no overall survival benefits compared with sorafenib alone, but may offer benefits in some subgroups of patients
Purpose of review The overview summarizes recent developments in radiation oncology for high risk and recurrent prostate cancer. Recent findings A number of well known phase III prostate hypofractionated radiation therapy (HFxRT) trials were finally published with long-term follow-ups. These trials demonstrate patterns of equivalent tumor control with several showing worse toxicity rates. The ASCENDE-RT randomized trial demonstrated the superiority of brachytherapy boost in intermediate and high-risk prostate cancer. Important randomized trials show a clear benefit to androgen deprivation therapy (ADT) in both interme...